» Articles » PMID: 27145366

BRG1 Targeting STAT3/VEGFC Signaling Regulates Lymphangiogenesis in Colorectal Cancer

Overview
Journal Oncotarget
Specialty Oncology
Date 2016 May 5
PMID 27145366
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor lymphangiogenesis is an important early event in tumorigenesis, one that promotes lymphatic metastasis. BRG1 (also known as SMARCA4) is a central component of the SWI/SNF chromatin-remodeling complex. In a previous work, we have reported that decreased BRG1 could promote colon cancer cell migration and invasion, and that the BRG1 expression level is negatively correlated with lymphatic metastasis. In the current study, we provide a comprehensive analysis of the role of BRG1 during lymphangiogenesis in colorectal cancer. Lymphatic vessels are more abundant in BRG1 low-expression tumors than in BRG1 high-expression tumors. We investigate the process by which BRG1 can promote VEGFC transcription and induce lymphangiogenesis in vivo and in vitro. We show that BRG1 controls lymphangiogenesis by binding to STAT3 and regulating STAT3 activation. We also prove the mechanisms through clinical samples. In summary, our demonstration of the important roles of the BRG1/STAT3/VEGFC in tumor-associated lymphangiogenesis might lead to the discovery of novel therapeutic targets in the treatment of cancers with BRG1 loss of function.

Citing Articles

Moxibustion Regulates the BRG1/Nrf2/HO-1 Pathway by Inhibiting MicroRNA-222-3p to Prevent Oxidative Stress in Intestinal Epithelial Cells in Ulcerative Colitis and Colitis-Associated Colorectal Cancer.

Wang X, Ji H, Yang Y, Zhang D, Kong X, Li X J Immunol Res. 2024; 2024:8273732.

PMID: 39359694 PMC: 11446618. DOI: 10.1155/2024/8273732.


The SMARCA4 mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer.

Zeng X, Yao B, Liu J, Gong G, Liu M, Li J NPJ Precis Oncol. 2023; 7(1):28.

PMID: 36922568 PMC: 10017700. DOI: 10.1038/s41698-023-00367-y.


Retracted Article: PKM2 overexpression protects against 6-hydroxydopamine-induced cell injury in the PC12 cell model of Parkinson's disease regulation of the brahma-related gene 1/STAT3 pathway.

Jiang L, Gao Y, Wang G, Zhong J RSC Adv. 2022; 9(26):14834-14840.

PMID: 35516344 PMC: 9064332. DOI: 10.1039/c9ra01760g.


FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma.

Dolatabadi S, Jonasson E, Andersson L, Santamaria M, Linden M, Osterlund T Front Oncol. 2022; 12:816894.

PMID: 35186752 PMC: 8851354. DOI: 10.3389/fonc.2022.816894.


Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma.

Lapidot M, Saladi S, Salgia R, Sattler M Front Pharmacol. 2022; 12:806570.

PMID: 35069219 PMC: 8776703. DOI: 10.3389/fphar.2021.806570.


References
1.
Xu Y, Zhang J, Chen X . The activity of p53 is differentially regulated by Brm- and Brg1-containing SWI/SNF chromatin remodeling complexes. J Biol Chem. 2007; 282(52):37429-35. DOI: 10.1074/jbc.M706039200. View

2.
Norrmen C, Tammela T, Petrova T, Alitalo K . Biological basis of therapeutic lymphangiogenesis. Circulation. 2011; 123(12):1335-51. DOI: 10.1161/CIRCULATIONAHA.107.704098. View

3.
Sundlisaeter E, Dicko A, Sakariassen P, Sondenaa K, Enger P, Bjerkvig R . Lymphangiogenesis in colorectal cancer--prognostic and therapeutic aspects. Int J Cancer. 2007; 121(7):1401-9. DOI: 10.1002/ijc.22996. View

4.
Bultman S, Herschkowitz J, Godfrey V, Gebuhr T, Yaniv M, Perou C . Characterization of mammary tumors from Brg1 heterozygous mice. Oncogene. 2007; 27(4):460-8. DOI: 10.1038/sj.onc.1210664. View

5.
Liu K, Luo Y, Lin F, Lin W . TopBP1 recruits Brg1/Brm to repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific control for cell survival. Genes Dev. 2004; 18(6):673-86. PMC: 387242. DOI: 10.1101/gad.1180204. View